Armata Pharma (ARMP)
4.22
-0.18 (4.09%)
Upcoming Events
Latest Headlines
Form 8-K Armata Pharmaceuticals, For: Sep 14
September 14, 2026 7:12 AM - SEC Filing
FDA grants Armata Pharmaceuticals breakthrough therapy status for AP-SA02
September 14, 2026 7:01 AM - StreetInsider
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
September 14, 2026 7:00 AM - PR NewsWire
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026 7:00 AM - PR NewsWire
Armata Pharmaceuticals publishes phage biology study in molecular journal
September 3, 2026 7:01 AM - StreetInsider
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
September 3, 2026 7:00 AM - PR NewsWire
Armata Pharmaceuticals, Inc. (ARMP) Tops Q2 EPS by 17c
August 12, 2026 4:47 PM - StreetInsider
Form 10-Q Armata Pharmaceuticals, For: Jun 30
August 12, 2026 4:23 PM - SEC Filing
Form 8-K Armata Pharmaceuticals, For: Aug 12
August 12, 2026 4:17 PM - SEC Filing
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
August 12, 2026 4:05 PM - PR NewsWire
Form 8-K Armata Pharmaceuticals, For: Jul 20
July 20, 2026 7:13 AM - SEC Filing
Form 8-K Armata Pharmaceuticals, For: Jul 17
July 20, 2026 7:13 AM - SEC Filing
Armata submits Phase 3 protocol to FDA for bacteriophage drug AP-SA02
July 20, 2026 7:00 AM - StreetInsider
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
July 20, 2026 7:00 AM - PR NewsWire
Form 4 Armata Pharmaceuticals, For: Jul 10 Filed by: Birx Deborah
July 14, 2026 4:19 PM - SEC Filing
Form 8-K Armata Pharmaceuticals, For: Jul 13
July 13, 2026 7:12 AM - SEC Filing
FDA agrees to Armata's pediatric study plan for AP-SA02 bacteremia drug
July 13, 2026 7:00 AM - StreetInsider
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
July 13, 2026 7:00 AM - PR NewsWire
Form S-8 Armata Pharmaceuticals,
July 13, 2026 6:02 AM - SEC Filing
Form 8-K/A Armata Pharmaceuticals, For: Apr 24
June 24, 2026 4:19 PM - SEC Filing
Form 8-K Armata Pharmaceuticals, For: Jun 23
June 23, 2026 7:11 AM - SEC Filing
Armata gets $2.5M more in DoD funding for bacteriophage drug
June 23, 2026 7:01 AM - StreetInsider
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
June 23, 2026 7:00 AM - PR NewsWire
Full Article List